Previous close | 32.00 |
Open | 31.49 |
Bid | 31.53 x 50000 |
Ask | 32.48 x 50000 |
Day's range | 31.49 - 31.49 |
52-week range | 22.35 - 34.48 |
Volume | |
Avg. volume | 116 |
Market cap | 61.06B |
Beta (5Y monthly) | 0.26 |
PE ratio (TTM) | 51.62 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 0.36 (1.13%) |
Ex-dividend date | 27 Sept 2024 |
1y target est | N/A |
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.